General Information of Drug (ID: DM6RBYT)

Drug Name
ALD-403 Drug Info
Synonyms MAb (migraine), Alder
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM6RBYT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eptinezumab DM5LJCI Migraine 8A80 Approved [3]
TEV-48125 DMMTKC6 Migraine 8A80 Phase 3 [4]
PF-4427429 DM3427C Migraine 8A80 Phase 1 [5]
CGRP DMCRPKS Asthma CA23 Discontinued in Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin gene-related peptide (CALC) TTAFORY NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT02275117) A Multicenter Assessment of ALD403 in Chronic Migraine. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.
5 Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
6 Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30.